Genital Erythrodysesthesia as a Severe Manifestation of Capecitabine Therapy: A Report of 3 Cases

ín, Beatriz Fleta-As

doi:10.1001/archdermatol.2011.257

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPE is a common side effect of capecitabine with a reported incidence of between 28-58% [4]. As of the time of this case report, there have been eight reported cases of PPE with the involvement of the scrotum and genitalia, including this one [5][6][7][8]. Despite the fact that PPE is seen in association with many other drugs used to treat malignancies, it appears as though the involvement of the genitals has been reported more commonly to the administration of capecitabine.…”

Section: Discussionmentioning

confidence: 80%

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation

Dricken

Pettke

Griffin

et al. 2020

Cureus

View full text Add to dashboard Cite

Capecitabine, a prodrug of fluorouracil, is a component of many chemotherapy regimens used to treat a wide variety of malignancies. One of the most common adverse reactions experienced by those who have been exposed to capecitabine is palmar-plantar erythrodysesthesia (PPE). PPE is a cutaneous manifestation of chemotherapy-related drug toxicity that has signs and symptoms of erythema, edema, pain, ulceration, or desquamation of the palms of the hands and soles of the feet. The signs and symptoms occur with varying severity. There are few reports of the genitalia being similarly affected. The following case describes a patient with locally advanced rectal cancer who experienced erythrodysesthesia secondary to a capecitabine-containing neoadjuvant chemoradiation regimen that primarily and most significantly involved the genitalia.

show abstract

Section: Discussionmentioning

confidence: 80%

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation

Dricken

Pettke

Griffin

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…However, to our knowledge, the coexistence of both genital and scrotal ulcerations together with PPE has been described in three patients only. 7,8 For that reason, there is no consistent grading system to describe scrotal and penile involvement associated with capecitabine. Sapp et al 7 suggest that the manifestations of PPE are similar to the symptoms experienced with scrotal and penile involvement, and that this variant should be incorporated into the grading system describing PPE.…”

mentioning

confidence: 99%

Unusual scrotal and penile ulcerations together with palmar‐plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine

Hadžavdić

Buzina

Murtezani

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series

Adames,

O’Brien,

Kelly

et al. 2024

Int J Colorectal Dis

View full text Add to dashboard Cite

Background Palmar-plantar erythrodysesthesia (PPE) is a slowly developing cutaneous reaction commonly experienced by patients treated with fluoropyrimidines. While erythrodysesthesia normally presents in a palmar-plantar distribution, it can also present with genital involvement, but this presentation is likely underreported and incorrectly attributed to an acute reaction from radiation therapy. This article aims to define erythrodysesthesia of the penis and scrotum as a rare but significant side effect of capecitabine. Case presentation We identified five cases of moderate to severe penis and scrotal erythrodysesthesia over a 2-year period at a large tertiary cancer center, representing an estimated incidence of 3.6% among male patients with rectal cancer who were treated with fluoropyrimidine-based chemoradiation within our institution. Conclusions Improved understanding of erythrodysesthesia involving the penis and scrotum can facilitate early identification and treatment of symptoms, and possibly prevent the discontinuation or delay of cancer treatment in patients treated with capecitabine and similar drugs. These clinical advances would improve and prolong patient quality of life during cancer treatment and prevent complications that result in hospitalization.

show abstract

Genital Erythrodysesthesia as a Severe Manifestation of Capecitabine Therapy: A Report of 3 Cases

Cited by 4 publications

References 7 publications

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation

Unusual scrotal and penile ulcerations together with palmar‐plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine

Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series

Contact Info

Product

Resources

About